Top

Published in:

Open Access 01-12-2021 | Cytostatic Therapy | Review

Focal adhesion kinase inhibitors, a heavy punch to cancer

Authors: Yueling Wu, Ning Li, Chengfeng Ye, Xingmei Jiang, Hui Luo, Baoyuan Zhang, Ying Zhang, Qingyu Zhang

Published in: Discover Oncology | Issue 1/2021

Abstract

Kinases are the ideal druggable targets for diseases and especially were highlighted on cancer therapy. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase and its aberrant signaling extensively implicates in the progression of most cancer types, involving in cancer cell growth, adhesion, migration, and tumor microenvironment (TME) remodeling. FAK is commonly overexpressed and activated in a variety of cancers and plays as a targetable kinase in cancer therapy. FAK inhibitors already exhibited promising performance in preclinical and early-stage clinical trials. Moreover, substantial evidence has implied that targeting FAK is more effective in combination strategy, thereby reversing the failure of chemotherapies or targeted therapies in solid tumors. In the current review, we summarized the drug development progress, chemotherapy strategy, and perspective view for FAK inhibitors.

Dawson JC, et al. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21(5):313–24.PubMedPubMedCentral

Lu Y, Sun H. Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK). J Med Chem. 2020;63(23):14382–403.PubMed

Jiang H, et al. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut. 2020;69(1):122–32.PubMed

Lee BY, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.PubMed

Diaz OC, et al. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Elife. 2019. https://doi.org/10.7554/eLife.47327.CrossRefPubMedPubMedCentral

Wang C, et al. Secreted pyruvate kinase M2 promotes lung cancer metastasis through activating the integrin Beta1/FAK signaling pathway. Cell Rep. 2020;30(6):1780-1797.e6.PubMed

Chen JS, et al. FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis. 2010;27(2):71–82.PubMed

Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14(9):598–610.PubMedPubMedCentral

Brullo C, Tasso B. New insights on Fak and Fak inhibitors. Curr Med Chem. 2021;28(17):3318–38.PubMed

10.

Tapial MP, Lopez NP, Lietha D. FAK structure and regulation by membrane interactions and force in focal adhesions. Biomolecules. 2020. https://doi.org/10.3390/biom10020179.CrossRef

11.

Cao FY, et al. Chemical structure characteristics and bioactivity of small molecule FAK inhibitors. Anticancer Agents Med Chem. 2016;16(8):934–41.PubMed

12.

Dunn KB, Heffler M, Golubovskaya VM. Evolving therapies and FAK inhibitors for the treatment of cancer. Anticancer Agents Med Chem. 2010;10(10):722–34.PubMedPubMedCentral

13.

Kandil SB, et al. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules. 2020. https://doi.org/10.3390/molecules25153488.CrossRefPubMedPubMedCentral

14.

Berger BT, et al. Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. Cell Chem Biol. 2021;28(5):686-698.e7.PubMed

15.

Lv P, Chen K, Zhu HL. Recent advances of small molecule focal adhesion kinase (FAK) inhibitors as promising anticancer therapeutics. Curr Med Chem. 2021. https://doi.org/10.2174/0929867328666210331143827.CrossRefPubMed

16.

Brami-Cherrier K, et al. FAK dimerization controls its kinase-dependent functions at focal adhesions. EMBO J. 2014;33(4):356–70.PubMedPubMedCentral

17.

Goni GM, et al. Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes. Proc Natl Acad Sci U S A. 2014;111(31):E3177–86.PubMedPubMedCentral

18.

He M, et al. Focal adhesion kinase is required for KSHV vGPCR signaling. Mol Carcinog. 2012;51(4):339–51.PubMed

19.

Choi CH, et al. pH sensing by FAK-His58 regulates focal adhesion remodeling. J Cell Biol. 2013;202(6):849–59.PubMedPubMedCentral

20.

Murphy JM, et al. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment. Exp Mol Med. 2020;52(6):877–86.PubMedPubMedCentral

21.

Cabrita MA, et al. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol. 2011;5(6):517–26.PubMedPubMedCentral

22.

Nguemgo KP, et al. The increased adhesion of tumor cells to endothelial cells after irradiation can be reduced by FAK-inhibition. Radiat Oncol. 2019;14(1):25.

23.

Tavora B, et al. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature. 2014;514(7520):112–6.PubMedPubMedCentral

24.

Huang M, et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci Transl Med. 2020. https://doi.org/10.1126/scitranslmed.aay7522.CrossRefPubMedPubMedCentral

25.

Jean C, et al. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol. 2014;204(2):247–63.PubMedPubMedCentral

26.

Lei X, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–33.PubMed

27.

Walsh C, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Therapy. 2010;9(10):778–90.

28.

Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res. 2009;11(5):R68.PubMedPubMedCentral

29.

Stokes JB, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011;10(11):2135–45.PubMedPubMedCentral

30.

Roma-Rodrigues C, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20040840.CrossRefPubMedPubMedCentral

31.

Lagares D, et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum. 2012;64(5):1653–64.PubMedPubMedCentral

32.

Iwatani M, et al. Discovery and characterization of novel allosteric FAK inhibitors. Eur J Med Chem. 2013;61:49–60.PubMed

33.

Lv PC, et al. FAK inhibitors in cancer, a patent review. Expert Opin Ther Patents. 2018;28(2):139–45.

34.

Otani H, et al. TAE226, a bis-anilino pyrimidine compound, inhibits the EGFR-mutant kinase including T790M mutant to show anti-tumor effect on EGFR-mutant non-small cell lung cancer cells. PLoS ONE. 2015;10(6): e0129838.PubMedPubMedCentral

35.

Moritake H, et al. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma. Cancer Med. 2019;8(18):7809–21.PubMedPubMedCentral

36.

Hu Z, Slayton WB. Integrin VLA-5 and FAK are good targets to improve treatment response in the Philadelphia chromosome positive acute lymphoblastic leukemia. Front Oncol. 2014;4:112.PubMedPubMedCentral

37.

Kurio N, et al. Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. Oral Oncol. 2012;48(11):1159–70.PubMed

38.

Hao HF, et al. Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. Biochem Biophys Res Commun. 2012;423(4):744–9.PubMed

39.

Le Large T, et al. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2021;40(1):91.PubMedPubMedCentral

40.

魏玉华, et al. 局部黏着斑激酶抑制剂治疗肿瘤的研究进展. 中华实验外科杂志, 2020. 37(06): 1167–1170.

41.

Al-Ghabkari A, et al. Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration. J Cancer Res Clin Oncol. 2019;145(6):1461–9.PubMed

42.

Yoon H, et al. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS ONE. 2014;9(2): e88587.PubMedPubMedCentral

43.

Stone RL, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Therapy. 2014;15(7):919–29.

44.

Verastem I. Study of PF-00562271, including patients with pancreatic, head and neck, prostatic neoplasms. 2013. https://ClinicalTrials.gov/show/NCT00666926.

45.

Infante JR, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30(13):1527–33.PubMed

46.

Jones SF, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(5):1100–7.PubMed

47.

Shimizu T, et al. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(5):997–1003.PubMedPubMedCentral

48.

Gerber DE, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020;139:60–7.PubMed

49.

Verastem I. Study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary clinical activity of defactinib in combination with avelumab in epithelial ovarian cancer. 2016. https://ClinicalTrials.gov/show/NCT02943317.

50.

Fennell DA, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND—a double-blind, randomized phase II study. J Clin Oncol. 2019;37(10):790–8.PubMed

51.

Mak G, et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer. 2019;120(10):975–81.PubMedPubMedCentral

52.

Soria JC, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2016;27(12):2268–74.PubMed

53.

Verastem, I. Dose escalation study in acute myeloid or B-cell acute lymphoblastic leukemia. 2014. https://ClinicalTrials.gov/show/NCT02215629.

54.

Doi T, et al. Phase I study of the focal adhesion kinase inhibitor BI 853520 in Japanese and Taiwanese patients with advanced or metastatic solid tumors. Target Oncol. 2019;14(1):57–65.PubMedPubMedCentral

55.

Kong DB, Chen F, Sima N. Focal adhesion kinases crucially regulate TGFbeta-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. OncoTargets Therapy. 2017;10:1783–92.PubMedPubMedCentral

56.

Mabeta P. PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation. Acta Pharm. 2016;66(3):399–410.PubMed

57.

Aboubakar NF, et al. Therapeutic potential of focal adhesion kinase inhibition in small cell lung cancer. Mol Cancer Ther. 2019;18(1):17–27.

58.

Stafman LL, et al. Focal adhesion kinase inhibition contributes to tumor cell survival and motility in neuroblastoma patient-derived xenografts. Sci Rep. 2019;9(1):13259.PubMedPubMedCentral

59.

Verastem I. A study of VS-6766 v. VS-6766 + defactinib in recurrent G12V or other KRAS-mutant non-small cell lung cancer. 2020. https://ClinicalTrials.gov/show/NCT04620330.

60.

Verastem, I. Phase I dose escalation study of VS-6063 in Japanese subjects with non-hematologic malignancies. 2017. https://ClinicalTrials.gov/show/NCT01943292.

61.

Verastem I. Phase II study of VS-6063 in patients with KRAS mutant non-small cell lung cancer. 2017.

62.

Verastem I. Placebo controlled study of VS-6063 in subjects with malignant pleural mesothelioma. 2017. https://ClinicalTrials.gov/show/NCT01870609.

63.

Thomas Jefferson University Verastem I. Defactinib and VS-6766 for the treatment of patients with metastatic uveal melanoma. 2021. https://ClinicalTrials.gov/show/NCT04720417.

64.

Ghosh AP, et al. Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget. 2017;8(17):29220–32.PubMedPubMedCentral

65.

Thanapprapasr D, et al. PTEN expression as a predictor of response to focal adhesion kinase inhibition in uterine cancer. Mol Cancer Ther. 2015;14(6):1466–75.PubMedPubMedCentral

66.

Zhang J, et al. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143–9.PubMedPubMedCentral

67.

Network UH. A Study of GSK2256098 and trametinib in advanced pancreatic cancer. 2020. https://ClinicalTrials.gov/show/NCT024282708.

68.

Muz B, et al. PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica. 2019;104(7):e310–3.PubMedPubMedCentral

69.

Jiang H, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–60.PubMedPubMedCentral

70.

Tiede S, et al. The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer. Oncogenesis. 2018;7(9):73.PubMedPubMedCentral

71.

Laszlo V, et al. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. J Mol Med (Berl). 2019;97(2):231–42.

72.

Osipov A, et al. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Cancer Biol Med. 2021;18(1):206–14.PubMedPubMedCentral

73.

Tomita N, et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013;23(6):1779–85.PubMed

74.

Altintop MD, et al. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors. Eur J Med Chem. 2018;155:905–24.PubMed

75.

Golubovskaya VM, et al. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis. 2012;33(5):1004–13.PubMedPubMedCentral

76.

O’Brien S, et al. FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget. 2014;5(17):7945–59.PubMedPubMedCentral

77.

Heffler M, et al. FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes. Anticancer Agents Med Chem. 2013;13(4):584–94.PubMedPubMedCentral

78.

Golubovskaya VM, et al. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther. 2013;12(2):162–72.PubMed

79.

Zhang H, et al. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Br J Cancer. 2016;115(2):203–11.PubMedPubMedCentral

80.

Steinestel K, et al. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma. Mol Oncol. 2020;14(2):248–60.PubMed

81.

Hochwald SN, et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle. 2009;8(15):2435–43.PubMed

82.

Kandil S, et al. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chem Biol Drug Des. 2018;91(1):314–21.PubMed

83.

Kurenova E, et al. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth. Oncotarget. 2013;4(10):1632–46.PubMedPubMedCentral

84.

Stewart JE, et al. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Mol Carcinog. 2015;54(1):9–23.PubMed

85.

Golubovskaya VM, et al. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer. 2013;13:342.PubMedPubMedCentral

86.

Institute of Cancer Research, U.K.V.I. Phase I Trial of VS-6063 and RO5126766. 2019. https://ClinicalTrials.gov/show/NCT03875820.

87.

Li BQ, et al. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 2019;451:48–57.PubMed

88.

Zhao X, et al. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biol. 2017;39(5):1010428317699120.PubMed

89.

Francois RA, et al. Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2015. https://doi.org/10.1093/jnci/djv123.CrossRefPubMedPubMedCentral

90.

Hopkins SKCCCaJ. Study of pembrolizumab with or without defactinib following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma. 2018. https://ClinicalTrials.gov/show/NCT03727880.

91.

Heffler M, et al. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Therapy. 2013;14(8):761–72.

92.

Wang S, et al. High-throughput chemical screening identifies focal adhesion kinase and aurora kinase B inhibition as a synergistic treatment combination in Ewing sarcoma. Clin Cancer Res. 2019;25(14):4552–66.PubMedPubMedCentral

93.

Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013;105(19):1485–95.PubMedPubMedCentral

94.

Halder J, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2018;67(22):10976–83.

95.

应世生物科技. IN10018联合标准化疗方案治疗高级别浆液性卵巢癌. 2020. http://www.chinadrugtrials.org.cn/CTR20200913.

96.

Hiscox S, et al. Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells. Breast Cancer Res Treat. 2011;125(3):659–69.PubMed

97.

Churchman ML, et al. Synergism of FAK and tyrosine kinase inhibition in Ph(+) B-ALL. JCI Insight. 2016. https://doi.org/10.1172/jci.insight.86082.CrossRefPubMedPubMedCentral

98.

Wang X, et al. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances antileukemia activity of venetoclax in acute myeloid leukemia. Mol Cancer Ther. 2020;19(8):1636–48.PubMedPubMedCentral

99.

Rolon-Reyes K, et al. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway. PLoS ONE. 2015;10(6): e0131059.PubMedPubMedCentral

100.

Lin HM, et al. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate. 2018;78(4):308–17.PubMed

101.

Zhou J, Yi Q, Tang L. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review. J Exp Clin Cancer Res. 2019;38(1):250.PubMedPubMedCentral

Title: Focal adhesion kinase inhibitors, a heavy punch to cancer
Authors: Yueling Wu
Ning Li
Chengfeng Ye
Xingmei Jiang
Hui Luo
Baoyuan Zhang
Ying Zhang
Qingyu Zhang
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Cytostatic Therapy
Ovarian Cancer
Ovarian Cancer
NSCLC
NSCLC
Ewing's sarcoma
Ewing's Sarcoma
Published in: Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-021-00449-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Identification hub genes of consensus molecular subtype correlation with immune infiltration and predict prognosis in gastric cancer

Diaphanous related formin 3 knockdown suppresses cell proliferation and metastasis of osteosarcoma cells

Attitudes among dermatologists regarding non-melanoma skin cancer treatment options

Role of 18F-PET-CT to predict pathological response after neoadjuvant treatment of rectal cancer

Perforated gastric cancer: a critical appraisal

Correction to: Identification hub genes of consensus molecular subtype correlation with immune infiltration and predict prognosis in gastric cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials